⚠️ Regulatory Notice: The DEA published a notice of intent to temporarily schedule 7-hydroxymitragynine in July 2026. Several states have already enacted bans. Verify your local laws before purchasing any 7-OH product.
Informational Guide · Kratom Alkaloid · Legal & Safety Review · 2026

GetBars 7-OH Tablets Review 2026: What Buyers Should Know

📅 October 26, 2026 🕐 12 min read ✎ CaresDigest Editorial Team 📋 Informational & Safety Guide

Key Points — GetBars 7-OH 2026

  • Product type: Flavored chewable tablets with 7-hydroxymitragynine (7-OH), a kratom-derived opioid receptor agonist
  • Two lines: Standard 7-OH (60 mg per tablet) and 7OH-Alternative (Mitraxidine blend, 300 mg per tablet)
  • Effects: Relaxation, sedation, mood changes; onset 30 min–2 hrs; duration 5–7 hrs
  • Legal status: DEA notice of intent to schedule issued July 2026; banned in Ohio, Tennessee & others
  • FDA stance: Not lawful in dietary supplements or conventional food under current federal law
  • Age gate: GetBars requires buyers to confirm they are 21 or older
  • Lab testing: Some batch reports published; not all flavors verified
  • Dependence risk: FDA and DEA cite addiction, tolerance, and withdrawal as significant concerns

What Is GetBars?

GetBars is a direct-to-consumer brand operated by 113 Ventures, LLC (California) that sells flavored chewable tablets formulated with 7-hydroxymitragynine — commonly referred to as 7-OH — derived from the Mitragyna speciosa plant, better known as kratom. The brand markets two product lines under the GetBars name: the original 7-OH line and a newer alternative line using a proprietary blend called Mitraxidine.

The brand positions itself around quality, consistency, and lab-tested purity. Its website requires visitors to confirm they are aged 21 or older before accessing product pages. GetBars ships domestically across the United States, though specific states are excluded depending on the product line. The company's contact email is Info@GetBars.co, and a customer service phone number (1-888-991-7471) appears in the privacy policy for mailing-list removal purposes.

GetBars 7-OH tablets — 7-hydroxymitragynine kratom alkaloid chewable tablets informational guide 2026

GetBars Product Lines: What's In Each?

GetBars currently offers two distinct product lines, each with different active compounds and formulations. Understanding what each line contains is essential for anyone researching these products.

🟦

Standard 7-OH Line

60 mg per tablet · 240 mg per pack

Flavors: Watermelon, White Grape, Mixed Berry, Blue Raspberry. Active compound is 7-hydroxymitragynine. Batch Watermelon (14-31-058) confirmed 60.5 mg per tablet via third-party lab analysis.

🟩

7OH-Alternative Line (NEW)

300 mg per tablet · 75 mg per serving

Flavors: Orange Citrus, Mixed Berry, Blue Raspberry, White Grape. Contains Mitraxidine — a proprietary kratom-derived blend. Lab report for Mixed Berry batch showed mitragynine at 7.454%; no 7-OH detected in that batch.

🏷️

Warehouse Sale (30 mg)

30 mg strength · Reduced pricing

A lower-strength option listed separately on the GetBars site. Specific flavor availability and current batch lab reports are not confirmed through independent review.

⚠️ Label Discrepancies Noted: Independent review of GetBars product pages identified conflicting strength listings across different pages — some showing 60 mg per tablet and others 30 mg for the same product lines. Buyers should verify the specific batch lab report that matches the product they are considering, rather than relying on marketing page descriptions alone.

What Is 7-Hydroxymitragynine? The Science Explained

7-hydroxymitragynine (abbreviated 7-OH or 7-HMG) is a naturally occurring alkaloid present in very small concentrations in kratom (Mitragyna speciosa) leaves — typically less than 2% of the total alkaloid content. However, it is also produced when the body metabolizes the primary kratom alkaloid, mitragynine, through the CYP3A4 liver enzyme pathway.

What makes concentrated 7-OH products like GetBars pharmacologically significant is the degree of concentration: isolated or concentrated 7-OH products contain orders of magnitude more of the compound than occurs in raw kratom leaf. Research has estimated 7-OH to be approximately 13 times more potent than morphine at mu-opioid receptors — the same receptor class targeted by prescription opioids including oxycodone, hydrocodone, and fentanyl.

How 7-OH Acts in the Body

7-hydroxymitragynine is a full mu-opioid receptor agonist. When taken orally as a tablet, it is absorbed through the gastrointestinal tract and crosses the blood-brain barrier, where it binds to opioid receptors and produces effects including relaxation, sedation, analgesia, and mood elevation. As an oral/edible product, onset is slower than inhaled or sublingual delivery — typically between 30 minutes and 2 hours — and effects tend to last 5 to 7 hours, varying by body weight, metabolism, and tolerance.

The CYP3A4 metabolism pathway also means that many common medications — including antifungals, antibiotics, antiretrovirals, certain antidepressants, and even grapefruit juice — can significantly alter how the body processes 7-OH, potentially leading to unexpectedly high plasma concentrations.

GetBars 7-OH chewable tablets — flavored kratom alkaloid supplement product lines White Grape Mixed Berry Watermelon Blue Raspberry 2026

GetBars Lab Testing: What the Reports Show

GetBars publishes batch-specific lab reports on its website, which is a meaningful transparency step compared to many competing products in this category. However, not all flavors and batches have verified reports available through independent review. Here is what confirmed lab results show:

Product / Batch 7-OH Result Mitragynine Verified
Watermelon 60mg (Batch 14-31-058) 60.5 mg / serving · 242 mg / pack Below quantitation limit Confirmed
Mixed Berry Alternative (Batch MB082526) Not detected 7.454% content Confirmed
Other flavors & batches Not independently verified Not independently verified Unverified
Note on lab reports: The two confirmed Watermelon batch records show differing client names, sample matrices, and weights between copies, which an independent review flagged as an inconsistency. Consumers should request the current batch report matching their specific order number and compare it against the product label before use.

Legal Status of GetBars and 7-OH in 2026

The legal landscape for 7-hydroxymitragynine in the United States changed significantly in 2026. Both federal agencies and individual states have taken action. Anyone considering purchasing GetBars products must understand the current regulatory status in their specific location.

Federal Status

At the federal level, 7-hydroxymitragynine is not currently classified as a scheduled controlled substance. However, the DEA published a Notice of Intent to Temporarily Schedule 7-OH on July 6, 2026 — the formal first step in placing a substance under emergency Schedule I status. Separately, on August 26, 2026, the DEA placed three related compounds — mitragynine pseudoindoxyl, MGM-15, and MGM-16 — under a temporary Schedule I order.

The FDA has separately stated that 7-hydroxymitragynine is not lawful in dietary supplements or conventional foods under the Federal Food, Drug, and Cosmetic Act, and has issued warning letters to companies marketing concentrated 7-OH products.

⚠️ Important: A Notice of Intent Is Not a Final Ban The DEA's July 2026 notice of intent begins a process — it is not a final scheduling action. However, this process typically concludes with temporary scheduling within weeks to months. Buyers who purchase products during this window may find the substance becomes federally illegal before their supply is consumed. Monitor DEA and FDA announcements through official government sources.

State-by-State Status

Several states have enacted their own restrictions on 7-hydroxymitragynine and kratom-derived products that are stricter than federal law. The following table reflects the status of verified information as of October 2026. This list is not exhaustive — always verify with your state's official legal sources.

State Status Notes
Ohio Banned 7-OH classified Schedule I effective May 19, 2026
Tennessee Banned Statewide kratom ban effective July 1, 2026
Alabama Banned Mitragynine & 7-OH listed as Schedule I controlled substances
Arkansas Banned Kratom listed as Schedule I controlled substance
Indiana Banned Mitragynine & 7-OH are synthetic controlled substances under state law
Rhode Island Banned Mitragynine listed as a Schedule I controlled substance
Vermont Banned Kratom listed as a regulated substance
Wisconsin Banned Mitragynine & 7-OH are Schedule I controlled substances
Federal (all states) Pending DEA notice of intent to schedule 7-OH published July 6, 2026
All other states Verify locally No confirmed ban — but state laws change frequently; check official state sources

Reported Effects and Safety Concerns

Because 7-hydroxymitragynine acts directly on mu-opioid receptors, its risk and benefit profile overlaps significantly with that of opioid medications. The FDA and DEA have both cited multiple safety concerns in formal communications about concentrated 7-OH products.

Commonly Reported Effects

The brand markets GetBars for "deep relaxation and mood elevation." Users in forums and reviews report effects including:

  • Physical relaxation and reduced tension
  • Mild to moderate euphoria or mood lift
  • Reduced perception of stress and anxiety
  • Drowsiness and sedation, particularly at higher amounts
  • Slowed thought patterns and reduced reaction time

Adverse Effects and Risks

Independent health agencies and published adverse event data document the following effects associated with 7-OH and concentrated kratom alkaloid products:

  • Common adverse effects: nausea, vomiting, constipation, dizziness, drowsiness, itching, sweating, impaired coordination
  • Serious effects: profound sedation, confusion, respiratory depression (slowed breathing), seizures, loss of consciousness
  • Drug interactions: Combined use with alcohol, opioids, benzodiazepines, antihistamines, or other CNS depressants dramatically increases the risk of respiratory depression and death
  • CYP3A4 interactions: Many common medications — including certain antibiotics, antifungals, and antidepressants — can increase 7-OH plasma levels, leading to unexpected intensity of effects
  • Dependence and withdrawal: Repeated use leads to tolerance, physical dependence, and opioid-like withdrawal upon cessation (anxiety, insomnia, sweating, muscle aches, gastrointestinal distress, cravings)
GetBars 7-OH tablet user experiences — informational guide to effects, risks, and safety considerations for 7-hydroxymitragynine 2026
⚠️ Combination Risk — Do Not Mix With Other Depressants The risk of serious injury or death increases substantially when any opioid-receptor agonist — including 7-OH — is combined with other central nervous system depressants. This includes alcohol, benzodiazepines (Xanax, Valium, Klonopin), opioid pain medications, muscle relaxants, and sleep aids. Even over-the-counter antihistamines (diphenhydramine/Benadryl) may increase sedation risk. If you take any prescription medications, consult your pharmacist or physician before using any kratom-derived product.

Pricing and Purchasing Information

GetBars is sold exclusively through its official website at getbars.co. Current pricing as of late 2026 is as follows:

  • Individual tablet packs (all flavors): $34.99 (sale from $49.99)
  • Variety Pack: $24.99 (sale from $35.99)
  • Subscribe & Save: 40% off plus free shipping on recurring orders
  • Multi-item discounts: 30% off 2 items; 35% off 3 or more items
  • Email signup offer: 40% off first order

Shipping is via USPS and takes approximately 5 to 8 business days. Free shipping applies to orders of $75 or more. The brand's refund policy offers a 30-day satisfaction guarantee on its refund page, while the Terms of Service under 113 Ventures, LLC allow returns of unopened, unused items within 60 days of purchase. Buyers should confirm current terms directly with the company before ordering.

Who Should Not Use GetBars or 7-OH Products

GetBars itself states on product pages that the product "may cause psychotropic effects" and advises consulting a physician before use. Based on the pharmacology of 7-hydroxymitragynine and guidance from federal health agencies, the following groups should not use these products:

  • Anyone under 21 years of age
  • Pregnant or breastfeeding individuals
  • People with a personal or family history of opioid use disorder, substance use disorder, or addiction
  • Anyone currently taking opioid pain medications, methadone, buprenorphine, or naltrexone
  • Anyone taking benzodiazepines, sleep medications, or muscle relaxants
  • Anyone consuming alcohol regularly or at the same time as the product
  • People with liver disease, kidney disease, or cardiovascular conditions
  • Anyone on medications that interact with the CYP3A4 enzyme pathway (ask your pharmacist)
  • People who are subject to drug testing in employment, legal, or athletic settings
  • Residents of states where 7-OH or kratom is classified as a controlled substance

🚨 Emergency Information

If someone is unresponsive, breathing slowly or not at all, has blue or gray lips, is seizing, or is severely confused after taking a 7-OH product, call 911 immediately.

Naloxone (Narcan) may be appropriate and should be administered if opioid exposure is known or suspected — it is available without a prescription at most pharmacies.

Poison Help Line: 1-800-222-1222 (24/7, free, confidential)

SAMHSA National Helpline: 1-800-662-4357 (24/7, free, substance use support)

Frequently Asked Questions

GetBars is a brand operated by 113 Ventures, LLC that sells flavored chewable tablets containing 7-hydroxymitragynine (7-OH), a concentrated alkaloid derived from the kratom plant. It offers two lines: a standard 7-OH formula (60 mg per tablet) and an alternative formula using a proprietary blend called Mitraxidine.
7-hydroxymitragynine is a psychoactive alkaloid found in small amounts in kratom leaves and produced when the body metabolizes mitragynine. It is a potent mu-opioid receptor agonist — the same receptor type targeted by prescription opioids — and concentrated 7-OH products contain far more of the compound than raw kratom leaf.
As of late 2026, the DEA has published a notice of intent to temporarily schedule 7-OH at the federal level (July 2026). The FDA states it is not lawful in dietary supplements or foods. Several states have already banned it, including Ohio (May 2026), Tennessee (July 2026), Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin. Buyers must check their specific state's laws before purchasing.
The brand markets tablets for relaxation and mood elevation. Effects typically begin 30 minutes to 2 hours after ingestion and may last 5 to 7 hours. Common adverse effects include nausea, dizziness, drowsiness, constipation, itching, and sweating. Serious effects can include sedation, respiratory depression, confusion, and seizure, particularly when combined with alcohol or other depressants.
GetBars publishes batch-specific lab reports on its website. The confirmed Watermelon 60mg batch (14-31-058) verified 60.5 mg of 7-OH per tablet. The Mixed Berry alternative batch showed mitragynine at 7.454% with no detectable 7-OH. Not all flavors and batches have independently verified reports available.
Standard workplace drug panels do not typically screen for 7-hydroxymitragynine. However, specialized urine, blood, hair, or saliva tests can detect the compound. Anyone subject to drug testing in employment, legal, or athletic contexts should factor this into their decision.
GetBars advertises a 30-day satisfaction guarantee. The Terms of Service under 113 Ventures, LLC allow returns of unopened, unused items within 60 days of purchase. Buyers should confirm current terms directly on the GetBars website, as policies may differ between pages.
Yes. Because 7-OH activates mu-opioid receptors, repeated use can lead to tolerance, physical dependence, and withdrawal upon cessation. Reported withdrawal effects include cravings, anxiety, insomnia, sweating, muscle aches, and gastrointestinal distress — similar to opioid withdrawal. The FDA and DEA have both cited dependence as a significant public health concern with concentrated 7-OH products.
These products are not appropriate for people under 21, pregnant or breastfeeding individuals, people with a history of opioid use disorder or addiction, anyone taking opioids, benzodiazepines, alcohol, or other CNS depressants, people with liver or kidney conditions, or anyone on medications metabolized by the CYP3A4 enzyme pathway. GetBars itself advises consulting a physician before use.
Call 911 immediately if someone is unresponsive, breathing slowly or not at all, has blue or gray lips, is having a seizure, or is severely confused. Naloxone (Narcan) may be appropriate when opioid exposure is known or suspected. For non-emergency poison questions, contact the Poison Help Line at 1-800-222-1222. For substance use support, SAMHSA's National Helpline is available 24/7 at 1-800-662-4357.
⚠️ Medical & Legal Disclaimer This article is for informational purposes only and does not constitute medical, legal, or purchasing advice. CaresDigest does not endorse, promote, or recommend the purchase or use of 7-hydroxymitragynine or any kratom-derived product. The legal status of these products changes frequently — always verify the current laws in your specific state and locality through official government sources. If you have questions about substance use or dependence, speak with a licensed healthcare professional.